Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published on August 28
Oral GLP-1 drugs could revolutionise patient experience by replacing daily injections with simple pills. This convenience factor could dramatically expand the market and boost patient adherence rates.
The obesity treatment market is worth billions, and successful oral alternatives could capture significant market share from established injectable treatments. Early movers stand to benefit most from this transition.
Eli Lilly's breakthrough has intensified competition, with multiple companies racing to develop their own oral solutions. This creates exciting opportunities for investors to back the next generation of winners.
Eli Lilly's successful oral weight-loss drug trial represents a pivotal shift in the multi-billion pound obesity treatment market. We believe this breakthrough signals the beginning of a new era where convenient, non-injectable therapies will challenge the dominance of current injectable treatments, creating significant opportunities for innovative pharmaceutical companies.
This group focuses on pharmaceutical and biotech companies developing the next generation of oral peptides, small molecule drugs, and alternative delivery mechanisms for metabolic diseases. These companies are at various stages of development, from early research to advanced clinical trials, representing different risk and reward profiles within the healthcare sector.
These companies were handpicked by professional analysts for their potential to capture market share in the rapidly growing weight-loss and diabetes treatment space. Each represents a strategic opportunity to benefit from the shift towards more convenient, patient-friendly treatments that could dramatically expand access and adherence to GLP-1 therapies.
Market capitalisation breakdown for the GLP-1 oral therapy-themed basket.
LLY: $756.76B
NVO: $180.85B
GPCR: $1.55B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+5
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
Here are a few of the assets in this group. Create an account to unlock the full list.
On average, analysts expect assets in this group to grow 489.93% over the next year.
12 of 13 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+489.93%
